CARLSBAD, Calif.--(BUSINESS WIRE)--Apr. 30, 2009-- Life Technologies Corporation (NASDAQ: LIFE), a provider of innovative life science solutions, today announced that it is providing its technologies to health officials across the globe to aid in the identification of influenza strains, particularly the strain associated with the recent outbreak of the influenza A H1N1 virus, also known as swine flu.

The company has formed a special 24-hour-a-day task force across key business units within Life Technologies to coordinate the company-wide response to global requests for assistance with the outbreak. The task force is leading efforts to provide health agencies with front line support such as instrument training, managing the supply chain to ensure that products get to customers as quickly as possible, and ensuring appropriate regulatory compliance. Also, Life Technologies is accelerating the manufacture of components that will be used by laboratories to test for and identify influenza.

“The spread of this new virus illustrates the importance of strong global surveillance programs,” said Mark Stevenson, President and Chief Operating Officer for Life Technologies. “Our technologies continue to be essential tools for public health agencies as they shift from reacting to the emergence of a potentially pandemic flu strain to proactively monitoring populations to identify the new strain as it arises.”

Life Technologies, through its Invitrogen and Applied Biosystems brands, offers components that support the workflow surrounding the identification of influenza virus strains. The company’s products include the MagMAX™ Viral RNA Isolation Kits for RNA purification; the SuperScript® III Platinum® One-Step qRT-PCR kit for amplification of viral RNA; TaqMan® Influenza A Detection Kit 2.0 for initial influenza type A screening; and several different capillary electrophoresis systems for determining the base-by-base sequence of viral samples. Additionally, the company offers its 7500 Fast and Fast Dx Real-Time PCR instruments under the Applied Biosystems brand.

Last September, the 7500 Fast Dx instrument received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for use with the CDC Human Influenza Virus Real-time RT-PCR Detection and Characterization Panel (rRT-PCR Flu Panel) from the U.S. Centers for Disease Control and Prevention (CDC). While both products received independent FDA 510(k) clearances, they are required to be used together as a system for the detection of influenza.

Due to this public health emergency, the FDA issued the CDC a Letter of Authorization to allow for the emergency use of a new CDC rRT-PCR detection panel for the swine flu. The authorization letter instructs qualified laboratories to perform the assay on an Applied Biosystems 7500 Fast Dx Real-Time PCR instrument or the 7500 Fast Real-Time PCR instrument.

About Life Technologies

Life Technologies Corporation (NASDAQ:LIFE) is a global biotechnology tools company dedicated to improving the human condition. Our systems, consumables and services enable researchers to accelerate scientific exploration, driving to discoveries and developments that make life even better. Life Technologies customers do their work across the biological spectrum, working to advance personalized medicine, regenerative science, molecular diagnostics, agricultural and environmental research, and 21st century forensics. Life Technologies had sales of more than $3 billion in 2008, employs approximately 9,500 people, has a presence in more than 100 countries, and possesses a rapidly growing intellectual property estate of approximately 3,600 patents and exclusive licenses. Life Technologies was created by the combination of Invitrogen Corporation and Applied Biosystems Inc. For more information on how we are making a difference please visit our website: www.lifetechnologies.com.

Life Technologies’ and its affiliates’ products are intended for research use only.

Safe Harbor Statement

This press release includes forward-looking statements about our anticipated results that involve risks and uncertainties. Some of the information contained in this press release, including, but not limited to, statements as to industry trends and Life Technologies’ plans, objectives, expectations and strategy for its business, contains forward-looking statements that are subject to risks and uncertainties that could cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Any statements that are not statements of historical fact are forward-looking statements. When used, the words “believe,” “plan,” “intend,” “anticipate,” “target,” “estimate,” “expect” and the like, and/or future tense or conditional constructions (“will,” “may,” “could,” “should,” etc.), or similar expressions, identify certain of these forward-looking statements. Important factors which could cause actual results to differ materially from those in the forward-looking statements are detailed in filings made by Life Technologies with the Securities and Exchange Commission. Life Technologies undertakes no obligation to update or revise any such forward-looking statements to reflect subsequent events or circumstances.

Source: Life Technologies Corporation

Life Technologies Corporation
Technology Public Relations
Renaldo Juanso
Renaldo.Juanso@lifetech.com
(415) 602-9849
or
Corporate Public Relations
Tim Ingersoll
Tim.Ingersoll@lifetech.com
(760) 918-3883